Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Communication, Symptom Burden, Psychological Distress, and Quality of Life Among Patients with Decompensated Cirrhosis.
Donlan J, Kaplan A, Noll A, Pintro K, Horick N, Zeng C, Edelen M, Soetan Z, Comrie C, Indriolo T, Li L, Zhu E, Armstrong ME, Thompson LL, Zhou J, Diop MS, Mason N, Engel KG, Rowland M, Kenimer S, O'Brien K, Lai JC, Jackson V, Chung RT, El-Jawahri A, Ufere NN. Donlan J, et al. Among authors: thompson ll. Clin Gastroenterol Hepatol. 2024 Nov 19:S1542-3565(24)01044-9. doi: 10.1016/j.cgh.2024.10.017. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39571876
Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study.
Reardon RM, Perlman KL, Asdourian MS, Shah N, Jacoby TV, Thompson LL, Reynolds KL, Semenov YR, Chen ST. Reardon RM, et al. Among authors: thompson ll. J Am Acad Dermatol. 2024 Jun;90(6):1268-1271. doi: 10.1016/j.jaad.2024.01.070. Epub 2024 Feb 9. J Am Acad Dermatol. 2024. PMID: 38341147 No abstract available.
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma.
Stephens MR, Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, Reynolds KL, Sullivan RJ, Foreman RK, Chen ST. Stephens MR, et al. Among authors: thompson ll. J Am Acad Dermatol. 2023 Jul;89(1):140-142. doi: 10.1016/j.jaad.2023.01.040. Epub 2023 Feb 15. J Am Acad Dermatol. 2023. PMID: 36806644 Free PMC article. No abstract available.
Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy.
Asdourian MS, Jacoby TV, Shah N, Otto T, Thompson LL, Dee EC, Reynolds KL, Semenov YR, Chen ST. Asdourian MS, et al. Among authors: thompson ll. J Am Acad Dermatol. 2023 Jun;88(6):1368-1370. doi: 10.1016/j.jaad.2022.12.049. Epub 2023 Feb 2. J Am Acad Dermatol. 2023. PMID: 36736625 Free PMC article. No abstract available.
Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition.
Jacoby TV, Shah N, Asdourian MS, Thompson LL, Otto TS, LeBoeuf NR, Semenov Y, Dee EC, Reynolds KL, Chen ST. Jacoby TV, et al. Among authors: thompson ll. J Am Acad Dermatol. 2023 Mar;88(3):711-714. doi: 10.1016/j.jaad.2022.09.012. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36113616 Free PMC article. No abstract available.
114 results